<![CDATA[Genmab — November 2025]]>Go weekend.. 🙂

]]>https://dev.proinvestor.com/forum/topic/399202/genmab-november-2025RSS for NodeSun, 07 Jun 2026 08:12:26 GMTSat, 01 Nov 2025 07:26:09 GMT60<![CDATA[Reply to Genmab — November 2025 on Sun, 30 Nov 2025 09:30:54 GMT]]>Donor-Derived T-Cell Redirection With Epcoritamab Achieving Complete Response After Early Post-Allo-HSCT Relapse of DLBCL https://onlinelibrary.wiley.com/doi/10.1002/jha2.70186

]]>https://dev.proinvestor.com/forum/post/7685773https://dev.proinvestor.com/forum/post/7685773Sun, 30 Nov 2025 09:30:54 GMT<![CDATA[Reply to Genmab — November 2025 on Fri, 28 Nov 2025 16:41:42 GMT]]>Genmab omkring kurs 2090 i US under pæn omsætning 🙂

]]>https://dev.proinvestor.com/forum/post/7685772https://dev.proinvestor.com/forum/post/7685772Fri, 28 Nov 2025 16:41:42 GMT<![CDATA[Reply to Genmab — November 2025 on Fri, 28 Nov 2025 14:09:05 GMT]]>Så vi kan forvente at Kina kommer ind fra højre med mange præperater vi evt. skal konkurrere med

]]>https://dev.proinvestor.com/forum/post/7685774https://dev.proinvestor.com/forum/post/7685774Fri, 28 Nov 2025 14:09:05 GMT<![CDATA[Reply to Genmab — November 2025 on Fri, 28 Nov 2025 14:08:40 GMT]]>
Link Preview Image
Ugens grafik: Kinas antibody-udvikling stormer frem

Ugens grafik handler om et af de emner, der langsomt men sikkert er på vej frem. Et emne der får mere og mere opmærksomhed

favicon

Økonomisk Ugebrev (ugebrev.dk)

]]>https://dev.proinvestor.com/forum/post/7685775https://dev.proinvestor.com/forum/post/7685775Fri, 28 Nov 2025 14:08:40 GMT<![CDATA[Reply to Genmab — November 2025 on Fri, 28 Nov 2025 10:22:15 GMT]]>tak for den gentogen

]]>https://dev.proinvestor.com/forum/post/7685771https://dev.proinvestor.com/forum/post/7685771Fri, 28 Nov 2025 10:22:15 GMT<![CDATA[Reply to Genmab — November 2025 on Fri, 28 Nov 2025 09:17:24 GMT]]>Impressive: The efficacy appeared impressive: ORR 96% and CR 88% that were maintained even in patients with high-risk features. Minimal residual disease negativity rate was 86%. Survival outcomes at 2 years look favorable as well: remaining in CR for the duration of the study, 82% = KYSO...

]]>https://dev.proinvestor.com/forum/post/7685769https://dev.proinvestor.com/forum/post/7685769Fri, 28 Nov 2025 09:17:24 GMT<![CDATA[Reply to Genmab — November 2025 on Fri, 28 Nov 2025 07:01:59 GMT]]>Blood: Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma https://ashpublications.org/blood/article/doi/10.1182/blood.2025029909/547148/Fixed-Duration-Epcoritamab-Plus-R2-Drives https://ashpublications.org/blood/article/146/22/2617/548279/Better-together-epcoritamab-boosts-R2-in-FL

]]>https://dev.proinvestor.com/forum/post/7685770https://dev.proinvestor.com/forum/post/7685770Fri, 28 Nov 2025 07:01:59 GMT<![CDATA[Reply to Genmab — November 2025 on Thu, 27 Nov 2025 12:20:29 GMT]]>Det er fuldstændig tosset at se på LLYs stigning, især i
forhold til Novo.

]]>https://dev.proinvestor.com/forum/post/7685765https://dev.proinvestor.com/forum/post/7685765Thu, 27 Nov 2025 12:20:29 GMT<![CDATA[Reply to Genmab — November 2025 on Wed, 26 Nov 2025 14:02:45 GMT]]>Synes nu mere at den seneste tids "lille" optur er mere et udtryk for stemningen her ændret sig i sektoren,,,, Ser lige at Eli Lilly er steget næsten 100% på 2,5 måned

]]>https://dev.proinvestor.com/forum/post/7685766https://dev.proinvestor.com/forum/post/7685766Wed, 26 Nov 2025 14:02:45 GMT<![CDATA[Reply to Genmab — November 2025 on Wed, 26 Nov 2025 09:36:54 GMT]]>25/11 21:02 Euroinvestor "Genmab: Stemningen er vendt - Investoren Helge Larsen sætter ord på udviklingen af Genmab aktien" 2 min https://www.euroinvestor.dk/nyheder/genmab-stemningen-er-vendt

]]>https://dev.proinvestor.com/forum/post/7685767https://dev.proinvestor.com/forum/post/7685767Wed, 26 Nov 2025 09:36:54 GMT<![CDATA[Reply to Genmab — November 2025 on Wed, 26 Nov 2025 09:07:26 GMT]]>Ja ups, den have jeg lige fået forkert registreret.

]]>https://dev.proinvestor.com/forum/post/7685768https://dev.proinvestor.com/forum/post/7685768Wed, 26 Nov 2025 09:07:26 GMT<![CDATA[Reply to Genmab — November 2025 on Wed, 26 Nov 2025 06:29:48 GMT]]>Ret beset ved vi vel ikke noget, men det hedder, at "Overall Survival (OS) is the primary endpoint in USA and in China, with the analysis population including all randomized participants.". Så måske den slags analyser også bare tager længere tid...

]]>https://dev.proinvestor.com/forum/post/7685764https://dev.proinvestor.com/forum/post/7685764Wed, 26 Nov 2025 06:29:48 GMT<![CDATA[Reply to Genmab — November 2025 on Tue, 25 Nov 2025 23:03:22 GMT]]>De har vel nået de events der skal til for at data er modne nok. Ellers skulle det måske være for at få en srre adskillelse på Epco og control armen. Men vi ved at endpoint er statistisk signifikant og dermed forskellen til ctrl armen eller hvad ?

]]>https://dev.proinvestor.com/forum/post/7685762https://dev.proinvestor.com/forum/post/7685762Tue, 25 Nov 2025 23:03:22 GMT<![CDATA[Reply to Genmab — November 2025 on Tue, 25 Nov 2025 17:39:33 GMT]]>I US og Kina er primary endpoint OS, så det passer nok meget godt, at data skal 'modne'

]]>https://dev.proinvestor.com/forum/post/7685760https://dev.proinvestor.com/forum/post/7685760Tue, 25 Nov 2025 17:39:33 GMT<![CDATA[Reply to Genmab — November 2025 on Tue, 25 Nov 2025 13:52:26 GMT]]>BOFA -GMAB top SMID pick with high conviction in 3 26E catalysts for >$5bn peak https://x.com/semodough/status/1993330204442316888

]]>https://dev.proinvestor.com/forum/post/7685759https://dev.proinvestor.com/forum/post/7685759Tue, 25 Nov 2025 13:52:26 GMT<![CDATA[Reply to Genmab — November 2025 on Tue, 25 Nov 2025 13:20:47 GMT]]>Den nyhed er vel kursdrivende, så jeg tror at de kommer med den når data er modne til offentliggørelse? Er der andre bud på det?

]]>https://dev.proinvestor.com/forum/post/7685757https://dev.proinvestor.com/forum/post/7685757Tue, 25 Nov 2025 13:20:47 GMT<![CDATA[Reply to Genmab — November 2025 on Tue, 25 Nov 2025 12:50:18 GMT]]>Havde håbet på Epco i DLBC, det havde en kærkommen julegave. Men tænker ikke de vil vente helt til EHA i Juni ??

]]>https://dev.proinvestor.com/forum/post/7685758https://dev.proinvestor.com/forum/post/7685758Tue, 25 Nov 2025 12:50:18 GMT<![CDATA[Reply to Genmab — November 2025 on Tue, 25 Nov 2025 11:45:02 GMT]]>@E L Yes, it was epco I had in mind when asking a while back, but this will do 😉 Let's hope for a good run up to ASH this year, and an even stronger finish in 2025.

]]>https://dev.proinvestor.com/forum/post/7685763https://dev.proinvestor.com/forum/post/7685763Tue, 25 Nov 2025 11:45:02 GMT<![CDATA[Reply to Genmab — November 2025 on Mon, 24 Nov 2025 18:46:27 GMT]]>ASH25 LBA-6
Abstract Title : Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice
of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients
(Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3
https://meetings-api.hematology.org/api/abstract/vmpreview/304640 Spectacular
...

]]>https://dev.proinvestor.com/forum/post/7685753https://dev.proinvestor.com/forum/post/7685753Mon, 24 Nov 2025 18:46:27 GMT<![CDATA[Reply to Genmab — November 2025 on Mon, 24 Nov 2025 15:19:54 GMT]]>seems that dump into that large auction follows huge auction in Novo?

]]>https://dev.proinvestor.com/forum/post/7685755https://dev.proinvestor.com/forum/post/7685755Mon, 24 Nov 2025 15:19:54 GMT<![CDATA[Reply to Genmab — November 2025 on Mon, 24 Nov 2025 15:06:26 GMT]]>@Plimsoller looks like only 6 again, i imagine you were probably hoping for something on epco, but this is nice i would say

]]>https://dev.proinvestor.com/forum/post/7685751https://dev.proinvestor.com/forum/post/7685751Mon, 24 Nov 2025 15:06:26 GMT<![CDATA[Reply to Genmab — November 2025 on Mon, 24 Nov 2025 15:02:31 GMT]]>ASH Late breaker for Teclistamab + Daratumumab
https://x.com/JacobPlieth/status/1992984045823942775/photo/1

]]>https://dev.proinvestor.com/forum/post/7685756https://dev.proinvestor.com/forum/post/7685756Mon, 24 Nov 2025 15:02:31 GMT<![CDATA[Reply to Genmab — November 2025 on Sat, 22 Nov 2025 11:10:12 GMT]]>Transcript : Genmabs præsentation på Jefferies Healthcare Conference med Q&A https://proinvestor.com/investornyt/1385876/transcript-genmabs-praeligsentation-paring-jefferies-healthcare-conference-med-qampa

]]>https://dev.proinvestor.com/forum/post/7685761https://dev.proinvestor.com/forum/post/7685761Sat, 22 Nov 2025 11:10:12 GMT<![CDATA[Reply to Genmab — November 2025 on Thu, 20 Nov 2025 14:31:22 GMT]]>Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street. https://www.investors.com/news/technology/biotech-stocks-antibody-drug-conjugates-adcs-cancer-treatment-chemotherapy/

]]>https://dev.proinvestor.com/forum/post/7685749https://dev.proinvestor.com/forum/post/7685749Thu, 20 Nov 2025 14:31:22 GMT